IceCure Medical Reports Data From Its Kidney Cancer Clinical Study Presented At Interventional Radiology Conference Dsud Minimally Invasive Approach Results In Shorter Hospitalization And Minor Impact On Renal Function

Author: Benzinga Newsdesk | June 12, 2024 08:32am

• ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate
• More data is expected in the fourth quarter of 2024, including data on patients with an average follow up of approximately 3 years 
• $6.92 billion global kidney cancer treatment market in 2024 expected to reach $8.78 billion by 2029—ProSense® is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries

CAESAREA, Israel, June 12, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that data from an interim analysis of its ICESECRET kidney cancer trial were presented at the 3rd Annual Israeli Conference on Interventional Radiology in Tel Aviv, Israel on June 10, 2024. Dr. Avivit Shoham, Deputy Director of the Vascular and Interventional Radiology Unit at Beilinson Rabin Medical Center, presented a session on Cryotherapy of Renal Malignancies in Israel, which included data previously shared in December 2022 at the Urological Association Conference in Eilat, Israel.

Posted In: ICCM